Bronchopleural fistula treatment: From the archetype of surgery to the future of stem cell therapy

Petrella, Francesco; Spaggiari, Lorenzo

doi:10.4103/0970-2113.152613

Cited by 4 publications

(3 citation statements)

References 14 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs that were undifferentiated are shown in Figure a. Their morphology was characteristic of human mesenchymal stem cells seen by Petrella et al and Keith et al . Differentiated cells are shown in panels b, c, and d of Figure (see the cell differentiation processes described in Materials and Methods section).…”

Section: Resultsmentioning

confidence: 68%

Effect of Photobiomodulation Therapy on the Increase of Viability and Proliferation of Human Mesenchymal Stem Cells

et al. 2019

View full text Add to dashboard Cite

Background and Objectives We have investigated how low intensity laser irradiation emitted by a multiwave‐locked system (MLS M1) affects the viability and proliferation of human bone marrow mesenchymal stem cells (MSCs) depending on the parameters of the irradiation. Study Design/Materials and Methods Cells isolated surgically from the femoral bone during surgery were identified by flow cytometry and cell differentiation assays. For irradiation, two wavelengths (808 and 905 nm) with the following parameters were used: power density 195, 230, and 318 mW/cm 2, doses of energy 3, 10, and 20 J (energy density 0.93–6.27 J/cm 2), and in continuous (CW) or pulsed emission (PE) (frequencies 1,000 and 2,000 Hz). Results There were statistically significant increases of cell viability and proliferation after irradiation at 3 J (CW; 1,000 Hz), 10 J (1,000 Hz), and 20 J (2,000 Hz). Conclusions Irradiation with the MLS M1 system can be used in vitro to modulate MSCs in preparation for therapeutic applications. This will assist in designing further studies to optimize the radiation parameters and elucidate the molecular mechanisms of action of the radiation. Lasers Surg. Med. © 2019 Wiley Periodicals, Inc.

show abstract

Section: Resultsmentioning

confidence: 68%

Effect of Photobiomodulation Therapy on the Increase of Viability and Proliferation of Human Mesenchymal Stem Cells

et al. 2019

View full text Add to dashboard Cite

show abstract

“…One of the most promising clinical applications of MSC technology in thoracic surgery is the minimally invasive management of post-resectional bronchopleural fistula (BPF), which is a pathological communication between the airways and the pleural cavity that may happen after major lung resections [91]. In oncologic lung resections, the incidence of BPF varies from 1% to 4%, but its mortality has been reported to range from 12.5% to 71.2%.…”

Section: Tissue Engineeringmentioning

confidence: 99%

Mesenchymal Stromal Cell Therapy for Thoracic Surgeons: An Update

Petrella,

Cassina,

Libretti

et al. 2023

JPM

Self Cite

View full text Add to dashboard Cite

Stem cells are undifferentiated cells presenting extensive self-renewal features and the ability to differentiate “in vitro” and “in vivo” into a range of lineage cells, like chondrogenic, osteogenic and adipogenic lineages when cultured in specific inducing media. Two major domains of clinical applications of stem cells in thoracic surgery have been investigated: regenerative medicine, which is a section of translational research in tissue engineering focusing on the replacement, renewal or regeneration of cells, tissues and organs to re-establish damaged physiologic functions; drug loading and delivery, representing a new branch proposing stem cells as carriers to provide selected districts with anti-cancer agents for targeted treatments.

show abstract

“…Although it is relatively rare, BPF has a life-threatening postoperative complication. Its postoperative morbidity after total pneumonectomy is 2∼20%; postoperative morbidity after lobectomia pulmonalis is 0.5∼3%, and its mortality is 16∼71% [1]. BPF recurrence rate after surgical repair is as high as 23.6% [2].…”

Section: Introductionmentioning

confidence: 99%

Clinical Observation of Modified Implantation of ASD Closure Device to Treat BPFs

Zhang

Chen

et al. 2022

Concepts in Magnetic Resonance Part A

View full text Add to dashboard Cite

Objectives. The aim of the paper is to explore the clinical efficacy and prognosis of the modified implantation of atrial septal defect (ASD) closure device to treat bronchopleural fistulas (BPFs). Methods. This paper has reviewed the results of 13 BPF patients implanted with a modified ASD closure device in Shaw Hospital Affiliated with the Medical College of Zhejiang University from October 2018 to November 2021. Anesthesia was selected based on the patient’s condition. Different sizes of ASD closures were selected based on the characteristics of fistulas. The modified implantation of the ASD closure device was applied to treat BPFs. The closure effects, closure time, and Borg score were observed at 4 weeks, 8 weeks, and 12 weeks after the surgery. Results. All 13 BPF patients were successfully implanted with the ASD closure device, and the immediate clinical remission rate was 100%. Follow-up at 4 weeks after the surgery showed that 2 cases were automatically discharged within a few days and 4 cases had closed fistula at 1 day after the surgery; follow-up at 8 weeks after the surgery showed that 1 case with fistula closure was observed at 55 days after the surgery; follow-up at 12 weeks after the surgery showed that 1 case with fistula closure was observed at 82 days after the surgery. T/P values (T = 7.90, 5.99, 7.44, P < 0.05 ) of paired t-tests before surgery and 4 weeks, 8 weeks, and 12 weeks after the surgery were rated by the Borg scale. The data were statistically different, and the clinical symptoms improved significantly. As of publication, the follow-up at 12 weeks after the surgery showed that the clinical remission rate was 9/11, namely, 81.8%, 3 of 11 cases had relieved clinical symptoms but still needed continuous drainage, and 2 cases had fistula closure. The median time of thoracic extubation was 63 (3,120) days. No patients died from surgical complications or BPF recurrence during the prognosis and the follow-up period. Conclusions. The modified implantation method has a high success rate and clinical remission rate, quick and early fistula closure, and simple and noninvasive operation, without the need for a dedicated delivery sheath and rigid endoscopy. Moreover, it has accurate positioning, reliable closure efficiency, and prognosis, and can be completed under local anesthesia. This reduces the operation time, difficulty, and risks of anesthesia.

show abstract

Bronchopleural fistula treatment: From the archetype of surgery to the future of stem cell therapy

Cited by 4 publications

References 14 publications

Effect of Photobiomodulation Therapy on the Increase of Viability and Proliferation of Human Mesenchymal Stem Cells

Effect of Photobiomodulation Therapy on the Increase of Viability and Proliferation of Human Mesenchymal Stem Cells

Mesenchymal Stromal Cell Therapy for Thoracic Surgeons: An Update

Clinical Observation of Modified Implantation of ASD Closure Device to Treat BPFs

Contact Info

Product

Resources

About